IASO BioMed (IASO) 10-K 24 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Apr. 19, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	IASO BioMed, Inc.
Entity Central Index Key	0001662907
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	Yes
Entity Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		37,248,744
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash	$ 140,234	$ 20,191
Prepaid expenses	1,451	1,562
Total current assets	141,685	21,753
TOTAL ASSETS	141,685	21,753
CURRENT LIABILITIES:
Accounts payable	92,901	64,427
Accounts payable, related party	43,000
Note payable, related party	60,000	60,000
Accrued salaries	402,500	187,500
Accrued board fees	140,000
Accrued interest, related party	5,803	2,203
Total current liabilities	744,204	314,130
TOTAL LIABILITIES	744,204	314,130
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' DEFICIT:
Preferred stock, $.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $.0001 par value, 100,000,00 shares authorized; 35,952,632 and 34,252,632 shares issued and outstanding	3,595	3,425
Additional paid-in capital	2,435,051	1,108,126
Accumulated deficit	(3,041,165)	(1,403,928)
Total shareholders' deficit	(602,519)	(292,377)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 141,685	$ 21,753

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par Value	$ .0001	$ .0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, Shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	35,952,632	34,252,632
Common stock, shares outstanding	35,952,632	34,252,632

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenues
Operating expenses:
General and administrative	1,325,637	543,326
Professional and consulting expense, related party	213,000
Research and development	95,000	171,078
Total operating expenses	1,633,637	714,404
Loss From Operations	(1,633,637)	(714,404)
Other Expenses:
Interest expense, related party	3,600	2,009
Total other expenses	3,600	2,009
Net Loss	$ (1,637,237)	$ (716,413)
Earnings per Common Share:
Basic and diluted loss per share	$ (0.05)	$ (0.02)
Weighted average number of common Shares outstanding:
Basic and diluted	35,194,755	33,837,920

Statement of Stockholders' Defi

Statement of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 3,343	$ 644,762	$ (687,515)	$ (39,410)
Balance, shares at Dec. 31, 2016	33,427,632
Sale of common stock	$ 57	231,443		$ 231,500
Sale of common stock, shares	575,000			15,000
Warrant exercises	$ 25	2,475		$ 2,500
Warrant exercises, shares	250,000
Share-based compensation		224,446		224,446
Contributed services		5,000		5,000
Net loss			(716,413)	(716,413)
Balance at Dec. 31, 2017	$ 3,425	1,108,126	(1,403,928)	(292,377)
Balance, shares at Dec. 31, 2017	34,252,632
Sale of common stock	$ 127	407,373		407,500
Sale of common stock, shares	1,275,000
Warrant exercises	$ 43	4,207		4,250
Warrant exercises, shares	425,000
Share-based compensation		915,345		915,345
Net loss			(1,637,237)	(1,637,237)
Balance at Dec. 31, 2018	$ 3,595	$ 2,435,051	$ (3,041,165)	$ (602,519)
Balance, shares at Dec. 31, 2018	35,952,632

Statement of Cash Flows

Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows from Operating Activities:
Net loss	$ (1,637,237)	$ (716,413)
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of stock for license fees
Share-based compensation	915,345	224,446
Contributed services		5,000
Changes in assets and liabilities:
Prepaid expenses	111	(170)
Accounts payable	71,474	35,631
Accrued salaries	215,000	187,500
Accrued board fees	140,000
Accrued interest, related party	3,600	2,006
Net cash used in operating activities	(291,707)	(262,000)
Cash Flows from Financing Activities:
Proceeds from issuance of notes payable, related party		53,000
Payments on notes payable, related party		(18,000)
Proceeds from sale of common stock	407,500	231,500
Proceeds from the exercise of warrants	4,250	2,500
Net cash provided by financing activities	411,750	269,000
Net Increase (Decrease) in Cash	120,043	7,000
Cash, beginning of period	20,191	13,191
Cash, end of period	140,234	20,191
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest, note payable - officer		$ 3

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations The Company follows accounting standards set by the Financial Accounting Standards Board, commonly referred to as the FASB. The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure they consistently report the Company’s financial condition, results of operations and cash flows. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification Cash and Cash Equivalents Use of Estimates Research and Development Costs Share-based Compensation The Company uses the Black-Scholes option-pricing model to estimate the fair value of warrants and the market price of our common stock, or comparable public companies if our stock is not trading, on the date of grant for the fair value. Our determination of fair value of share-based awards is affected by those stock prices as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate. Income Taxes Fair Value of Financial Instruments Earnings Per Share Recently Issued Accounting Pronouncements Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending September 30, 2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 will have a significant impact on its financial statements upon adoption.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. Going Concern At December 31, 2018 and December 31, 2017, the Company had cash of $140,234 and $20,191, respectively. It also had working capital deficit of $602,519 and $292,377, respectively and an accumulated deficit of $3,041,165 and $1,403,928, respectively. This raises substantial doubt about the Company’s ability to continue as a going concern. Management is taking action to ensure the Company will continue as a going concern for at least one year beyond the date of the issuance of the Company’s financial statements. From March 11, 2015 (Inception) through December 31, 2017, the Company has sold $971,842 in common stock. Common stock sales will continue as the Company seeks private placement offerings of its common stock. These fundraising efforts may not be successful. While there can be no assurances, management believes that these actions will enable the Company to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	3. Related Party Transactions Note Payable In October 2017, the Company executed an unsecured promissory note to Richard Schell for $35,000 bearing interest at 6% per annum, which remained outstanding at December 31, 2018 and December 31, 2017 with accrued interest payable of $2,606 and $506, respectively. A total of $3,600 and $2,009 of interest expense was accrued during the years ended December 31, 2018 and 2017, respectively. Employment Agreements In March 2017 the Company entered into an employment agreement with its CFO for a two-year term. The CFO will assume his responsibilities on a part time basis until requested by the Board of Directors to become a full-time executive. The base salary of $75,000 per annum is payable to the CFO only upon the Company’s raising of an additional $750,000. When the CFO becomes a full-time executive, his salary will be increased to $125,000 per annum, which has not yet occurred. The CFO also received warrants to purchase 500,000 shares of the Company’s common stock at $0.40 per share for a period of five years after issuance; 250,000 warrants vested upon signing the agreement and the remaining 250,000 vested in March 2018. The CFO will also be eligible to earn discretionary annual performance bonuses upon meeting certain objectives as determined by the Board of Directors, none of which have been earned to date. The agreement provides for severance payments. The Company accrued $225,000 and $187,500 in salaries related to these agreements for years ended December 31, 2018 and 2017, respectively. During the year period ended December 31, 2018, $10,000 was paid to these officers from fees accrued under these agreements. Contributed Services Scientific Advisory Board Agreements Also, effective March 1, 2018, we entered into a Scientific Advisory Board Agreement with our director Dr. Karatzas (the “Karatzas Agreement”), through which Dr. Karatzas agreed to serve on our Scientific Advisory Board. The term of the Karatzas Agreement is one year from execution and may be renewed annually by mutual consent of both parties. The Karatzas Agreement provides for payments as follows: an annual fee of $25,000; a signing bonus of $50,000 payable after successful closing of any cumulative minimum $1,000,000 investment in the Company; a non-discretionary bonus of $40,000 payable following a successful financing round of a minimum of $2,000,000; and should the Karatzas Agreement be renewed after one year, a $90,000 bonus payable only after the signing bonus and non-discretionary bonus from year one have been earned. In order to receive the non-discretionary bonus payments Dr. Karatzas must be actively involved in the creation and execution of strategies necessary for the Company to achieve its strategic plan including the scientific, commercial and business objectives, as applicable and as agreed upon between the Dr. Karatzas and the Company’s Chief Executive Officer. The Company accrued a total of $150,000 in fees related to these agreements for the year ended December 31, 2018, which includes $50,000 in fees and $100,000 in signing bonuses. The company paid a total of $10,000 in accrued fees under these agreements during the year ended December 31, 2018. Services Agreement he Company pays a company owned by the Company’s Corporate Secretary’s $400 per month for reimbursement of certain administrative office expenses such as computer, internet, phone and similar items. The agreement is on a month-to-month basis and may be terminated at any time by either party. Total expense for the years ended December 31, 2018 and 2017 was $4,800. Consulting Agreement and other Payments

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Equity	4. Stockholders’ Equity The Company has the authority to issue 110,000,000 shares of $.0001 par value stock, of which 100,000,000 shares are common stock and 10,000,000 shares are preferred stock. As of December 31, 2018, and December 31, 2017 there were 35,952,632 and 34,252,632 common stock shares issued and outstanding. For the year ended December 31, 2018, the Company sold a total of $407,500 through private placements as follows: 250,000 shares of our common stock at $0.40 per share that included warrants to purchase up to 250,000 shares of our common stock exercisable at $0.75 per share for a period of three years from issuance; and 1,025,000 shares of our common stock at $0.30 per share that included warrants to purchase up to 1,025,000 shares of our common stock exercisable at $0.05 per share for a period of three years from issuance. During the year ended December 31, 2018, the Company issued warrants to purchase up to 960,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 100,000 of which expire in October 2023, 400,000 of which expire in December 2022 and 460,000 of which expire in February 2021. Subsequent to issuance, 425,000 of these warrants were exercised during the year ended December 31, 2018 for proceeds to the Company of $4,250. We incurred stock compensation expense totaling $376,668 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation. During the year ended December 31, 2018, the Company issued warrants to purchase up to 140,000 shares of common stock at an exercise price of $0.01 per share, and expire in September 2019, through execution of agreements with new members of our Scientific Advisory Board. We incurred stock compensation expense totaling $54,876 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation. During the year ended December 31, 2018, the Company issued warrants to purchase up to 1,161,112 shares of common stock at an exercise price of $0.001 per share, and expire in September 2019, through execution of agreements with new members of our Scientific Advisory Board. We incurred stock compensation expense totaling $463,299 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation. For the year ended December 31, 2017, the Company sold $224,000 in its private placement, issuing 560,000 shares of our common stock at $0.40 per share that included warrants to purchase up to 310,000 shares of our common stock exercisable at $0.75 per share, as well as warrants to purchase up to 250,000 shares of our common stock at $0.01 per share, all for a period of three years from issuance. In July 2017 the Company issued 250,000 shares of its common stock at $0.01 per share upon exercise of the warrant exercisable at $0.01 per share issued in the private placement for total proceeds of $2,500. For the year ended December 31, 2017, the Company issued 15,000 shares of commons stock for total proceeds of $7,500 through its S-1 Registration Statement at $0.50 per share.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Royalties ● CAD $5,000 on the issuance of the first US patent ● CAD $25,000 on the filing of an investigational new drug application or regulatory filing ● CAD $50,000 on the initiation of the first Phase II clinical study ● CAD $100,000 on the initiation of the first Phase III clinical study ● CAD $300,000 on receipt of regulatory approval The Company must also pay milestone payments as follows for the out of body test to identify Alzheimer’s disease as follows: ● CAD $5,000 on the issuance of the first US patent ● CAD $50,000 on the filing of a 510(k) or PMA application ● CAD $200,000 on receipt of regulatory approval In addition, the Company issued 5% of the total number of issued and outstanding shares in the Company’s Series A financing to the same institution, or 1,652,632 shares in March 2016. This agreement, payable in Canadian dollars, exposes the Company to foreign exchange transaction gains and losses. In August 2016, the Company issued an additional 300,000 shares of the Company’s common stock to McGill in lieu of the pre-existing anti-dilution provision. As McGill owns more than 5% of the Company’s outstanding common stock, it is considered a related party. Research Agreement Scientific Advisory Board

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation	6. Share-based Compensation In March 2017, the Company issued 750,000 warrants to the Company’s officers to purchase shares of our common stock at $0.40 per share. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 1.55 % Expected term 3 years Volatility 154 % Dividend yield — Fair value $ 0.33 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $20,502 and $224,446 for the years ended December 31, 2018 and 2017, respectively. In February and March 2018 the Company issued warrants to purchase up to 860,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 400,000 of which were to expire in December 2022 and 460,000 of which expire in February 2021. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.33 – 2.34 % Expected term 2.5 years Volatility 115-137 % Dividend yield - Fair value $ 0.39 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $336,926 for the year ended December 31, 2018. In September 2018 the Company issued warrants to purchase up to 140,000 shares of common stock at an exercise price of $0.01 per share to new members of our Scientific Advisory Board that expire in September 2019. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.49 – 2.57 % Expected term 1.0 years Volatility 222 % Dividend yield - Fair value $ 0.39 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $54,876 for the year ended December 31, 2018. In October 2018 the Company issued a warrant to purchase up to 100,000 shares of stock at an exercise price of $0.01 per share to business and scientific consultant that expires in October 2023. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.85 % Expected term 2.5 years Volatility 237 % Dividend yield - Fair value $ 0.40 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to this warrant was $39,741 for the year ended December 31, 2018. In October 2018 the Company issued warrants to purchase up to 1,161,112 shares of stock at an exercise price of $0.001 per share to each of the Company’s CFO (950,000 shares) and Corporate Secretary (211,112 shares) that were due to expire, but were exercised, in January 2019 (See Note 9 – Subsequent Events below). Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.41 % Expected term 2.5 years Volatility 239 % Dividend yield - Fair value $ 0.40 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $463,299 for the year ended December 31, 2018. Warrants A summary of the activity of the Company’s outstanding warrants at December 31, 2018 and December 31, 2017 is as follows: Warrants Weighted-average exercise price Weighted-average grant date fair value Outstanding and exercisable at December 31, 2016 8,075,000 $ 0.35 $ 0 Granted 935,000 0.41 0.33 Expired/Cancelled - - - Exercised (250,000 ) 0.01 - Outstanding and exercisable at December 31, 2017 8,760,000 $ 0.35 $ 0.33 Granted 4,061,112 0.13 0.39 Expired/Cancelled - - - Exercised (425,000 ) 0.01 - Outstanding and exercisable at December 31, 2018 12,396,112 $ 0.31 $ 0.36 The following table sets forth the exercise price range, number of shares, weighted average exercise price and remaining contractual lives of the warrants by groups as of December 31, 2018: Exercise price range Number of options outstanding Weighted-average exercise price Weighted-average remaining life $ 0.001 - $0.01 1,836,112 $ 0.003 1.9 years $ 0.05 1,025,000 $ 0.05 2.7 years $ 0.10 3,000,000 $ 0.10 1.6 years $ 0.40 750,000 0.40 3.2 years $ 0.50 5,000,000 0.50 1.6 years $ 0.75 785,000 0.75 1.6 years 12,396,112 $ 0.37 2.1 years

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The components of the net deferred tax assets recognized as of December 31, 2018 and 2017 are as follows: 2018 2017 Deferred tax assets: Capitalized start-up costs 638,645 447,336 Deferred tax asset 638,645 447,336 Valuation allowance (638,645 ) (447,336 ) Net deferred tax assets $ – $ – A reconciliation of statutory tax rates to effective tax rates were as follows in each of the periods presented: 2018 2017 Federal income taxes at statutory rate 21.00 % 34.00 % State income taxes at statutory rate 4.63 % 4.63 % Valuation allowance (25.63 )% (38.63 )% Effective tax rate 0.00 % 0.00 % As of December 31, 2018 and 2017 the Company had capitalized start-up costs for tax purposes of approximately $3,041,165 and $1,403,928, respectively, which will be amortized over 15 years upon commencement of business operations. As of December 31, 2018 and 2017, an evaluation of the deferred tax asset determined that it was more likely than not that the start-up cost asset may not be realized, and therefore a valuation allowance for $638,645 and $477,336, respectively, was recorded. The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the periods ended December 31, 2018 and 2017, the Company did not recognize any interest or penalties in its statement of operations, nor did it have any interest or penalties accrued in its balance sheets at December 31, 2018 and 2017 relating to unrecognized tax benefits. Under the provisions of ASC 740, Accounting for Uncertainty in Income Taxes

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events On November 1, 2018, the Registrant’s Board approved the issuance of warrants to purchase shares of the Corporation’s common stock to two of its executive officers. Mr. Duane C. Knight, Chief Financial Officer of the Registrant, received a warrant to purchase up to 950,000 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Mr. Thomas B. Olson, Corporate Secretary of the Registrant, received a warrant to purchase up to 211,112 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Messrs. Knight and Olson exercised these warrants in January 2019. On January 5, 2019, the Board of Directors of IASO BioMed, Inc. (the “Registrant”) approved the following extensions to certain Employment and Scientific Advisory Board Agreements (together the “Agreements”) with its Officers and Directors that were set to expire during the first quarter of 2019 including: ● Extension for a period of two (2) years of the Employment Agreement between IASO BioMed, Inc. and Richard M. Schell, originally effective March 1, 2017; and ● Extension for a period of two (2) years of the Employment Agreement between IASO BioMed, Inc. and Duane Knight, originally effective March 1, 2017; and ● Extension for a period of one (1) year of the Scientific Advisory Board Agreement by and between IASO BioMed, Inc. and Dr. Vassilios Papadopoulos dated as of March 1, 2018; and ● Extension for a period of two (2) years of the Scientific Advisory Board Agreement by and between IASO BioMed, Inc. and Dr. Costas Karatzas dated as of March 1, 2018. Each of the above Agreements were extended under the terms and conditions contained in the Agreements in effect at the time of the extensions with no alteration except for the new Agreement end dates. Each of the directors abstained on voting for extension of their Agreement. In January 2016 the Company signed a Research Agreement with The Research Institute of the McGill University Health Centre (RIMUHC) in Canada for research activities on the Company’s potential products that was amended in March 2017. The Company agreed in June 2018 to an additional payment of $65,000 to continue research and development activities at RIMUHC and signed an extension of the agreement in January 2019 that includes an additional payment of $35,000 in 2019, which has not yet been paid. Management has determined that there are no further events subsequent to the balance sheet date that should be disclosed in these financial statements.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations The Company follows accounting standards set by the Financial Accounting Standards Board, commonly referred to as the FASB. The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure they consistently report the Company’s financial condition, results of operations and cash flows. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification
Cash and Cash Equivalents	Cash and Cash Equivalents
Use of Estimates	Use of Estimates
Research and Development Costs	Research and Development Costs
Share-based Compensation	Share-based Compensation The Company uses the Black-Scholes option-pricing model to estimate the fair value of warrants and the market price of our common stock, or comparable public companies if our stock is not trading, on the date of grant for the fair value. Our determination of fair value of share-based awards is affected by those stock prices as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Income Taxes	Income Taxes
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Earnings Per Share	Earnings Per Share
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending September 30, 2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 will have a significant impact on its financial statements upon adoption.

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Estimated Fair values of Warrants Granted Using the Black-Scholes Option Pricing Model	Risk-free interest rate 1.55 % Expected term 3 years Volatility 154 % Dividend yield — Fair value $ 0.33 Risk-free interest rate 2.33 – 2.34 % Expected term 2.5 years Volatility 115-137 % Dividend yield - Fair value $ 0.39 Risk-free interest rate 2.49 – 2.57 % Expected term 1.0 years Volatility 222 % Dividend yield - Fair value $ 0.39 Risk-free interest rate 2.85 % Expected term 2.5 years Volatility 237 % Dividend yield - Fair value $ 0.40 Risk-free interest rate 2.41 % Expected term 2.5 years Volatility 239 % Dividend yield - Fair value $ 0.40
Schedule of Warrant Activity	A summary of the activity of the Company’s outstanding warrants at December 31, 2018 and December 31, 2017 is as follows: Warrants Weighted-average exercise price Weighted-average grant date fair value Outstanding and exercisable at December 31, 2016 8,075,000 $ 0.35 $ 0 Granted 935,000 0.41 0.33 Expired/Cancelled - - - Exercised (250,000 ) 0.01 - Outstanding and exercisable at December 31, 2017 8,760,000 $ 0.35 $ 0.33 Granted 4,061,112 0.13 0.39 Expired/Cancelled - - - Exercised (425,000 ) 0.01 - Outstanding and exercisable at December 31, 2018 12,396,112 $ 0.31 $ 0.36
Schedule of Stock Options Exercise Price	The following table sets forth the exercise price range, number of shares, weighted average exercise price and remaining contractual lives of the warrants by groups as of December 31, 2018: Exercise price range Number of options outstanding Weighted-average exercise price Weighted-average remaining life $ 0.001 - $0.01 1,836,112 $ 0.003 1.9 years $ 0.05 1,025,000 $ 0.05 2.7 years $ 0.10 3,000,000 $ 0.10 1.6 years $ 0.40 750,000 0.40 3.2 years $ 0.50 5,000,000 0.50 1.6 years $ 0.75 785,000 0.75 1.6 years 12,396,112 $ 0.37 2.1 years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Deferred Tax Assets and Liabilities	The components of the net deferred tax assets recognized as of December 31, 2018 and 2017 are as follows: 2018 2017 Deferred tax assets: Capitalized start-up costs 638,645 447,336 Deferred tax asset 638,645 447,336 Valuation allowance (638,645 ) (447,336 ) Net deferred tax assets $ – $ –
Schedule of Income Tax Rate Reconciliation	A reconciliation of statutory tax rates to effective tax rates were as follows in each of the periods presented: 2018 2017 Federal income taxes at statutory rate 21.00 % 34.00 % State income taxes at statutory rate 4.63 % 4.63 % Valuation allowance (25.63 )% (38.63 )% Effective tax rate 0.00 % 0.00 %

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Research and development costs	$ 95,000	$ 171,078
Antidilutive securities excluded from computation of earnings per share, amount	12,396,112	8,760,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	31 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 20,191	$ 140,234
Working capital deficit	292,377	602,519
Accumulated deficit	(1,403,928)	$ (3,041,165)
Sold common stock, value	$ 971,842

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 01, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016
Related Party Transaction [Line Items]
Interest expense				$ 3,600	$ 2,009
Accrued salaries				402,500	187,500
Accrued fees				10,000
Warrants [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock						1,161,112
Employment Agreement [Member]
Related Party Transaction [Line Items]
Accrued salaries				225,000	187,500
Fees paid to officers				10,000
Papadopoulos Agreement [Member]
Related Party Transaction [Line Items]
Annual fees	$ 35,000
Amount awarded to serve as scientific advisory board	10,000
Signing bonus payable on closing of cumulative minimum investment	50,000
Cumulative minimum investment	1,000,000
Non-discretionary bonus	45,000
Financing round of minimum payment	2,000,000
Bonus payable	95,000
Karatzas Agreement [Member]
Related Party Transaction [Line Items]
Annual fees	25,000
Signing bonus payable on closing of cumulative minimum investment	50,000
Cumulative minimum investment	1,000,000
Non-discretionary bonus	40,000
Financing round of minimum payment	2,000,000
Bonus payable	$ 90,000
Scientific Advisory Board Agreements [Member]
Related Party Transaction [Line Items]
Accrued fees				150,000
Agreement related fees				50,000
Value of signing Bonuses, related with agreements				100,000
Services Agreement [Member]
Related Party Transaction [Line Items]
Reimbursement charges per month				400
Services Agreement [Member] | Corporate Secretary [Member]
Related Party Transaction [Line Items]
Reimbursement Expense				4,800	4,800
Consulting Agreement and Other Payments [Member]
Related Party Transaction [Line Items]
Accrued fees				45,000
Agreement related fees				5,000
Additional consulting services fee paid				$ 18,000
Consulting agreement, term				2 years
Consulting Agreement and Other Payments [Member] | March 1, 2018 [Member]
Related Party Transaction [Line Items]
Agreement related fees				$ 5,000
Richard Schell, CEO [Member]
Related Party Transaction [Line Items]
Note payable, related party								$ 25,000
Notes payable, bearing interest percentage								6.00%
Accrued interest payable				3,197	1,697
Richard Schell, CEO [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Agreement term			2 years
Base salary			$ 150,000
Additional capital to be raised as target			$ 750,000
Warrants to purchase common stock			250,000
Warrants, exercise price			$ 0.40
Warrants term			5 years
Richard Schell, CEO [Member] | Employment Agreement [Member] | Warrants [Member]
Related Party Transaction [Line Items]
Warrants, vested		125,000	125,000
Richard Schell, CEO [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Note payable, related party							$ 35,000
Notes payable, bearing interest percentage							6.00%
Accrued interest payable				2,606	$ 506
CFO [Member] | Warrants [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock						950,000
CFO [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Agreement term			2 years
Base salary			$ 75,000
Additional capital to be raised as target			$ 750,000
Warrants to purchase common stock			500,000
Warrants, exercise price			$ 0.40
Increase salary per annum			$ 125,000
CFO [Member] | Employment Agreement [Member] | Warrants [Member]
Related Party Transaction [Line Items]
Warrants, vested		250,000	250,000
CEO and CFO [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Compensation expenses				$ 5,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2018	Mar. 31, 2018	Feb. 28, 2018
Class of Stock [Line Items]
Number of shares authorized to issue		110,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Common stock, shares authorized		100,000,000	100,000,000
Preferred stock, shares authorized		10,000,000	10,000,000
Common stock, shares issued		35,952,632	34,252,632
Common stock, shares outstanding		35,952,632	34,252,632
Proceeds from issuance of stock through private placements		$ 407,500
Issuance of common stock			15,000
Stock price per share			$ 0.50
Proceeds from the exercise of warrants		4,250	$ 2,500
Proceeds from common stock			7,500
Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock				1,161,112
Warrants exercise price				$ 0.001
Stock compensation expense		$ 463,299
New Members of Our Scientific Advisory Board One [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock		140,000
Warrants exercise price		$ 0.01
Warrants expiration date		Sep. 30, 2019
Stock compensation expense		$ 54,876
New Members of Our Scientific Advisory Board Two [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock		1,161,112
Warrants exercise price		$ 0.001
Warrants expiration date		Sep. 30, 2019
Stock compensation expense		$ 463,299
December 2023 [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock		100,000
Warrants expiration date		Oct. 31, 2023
December 2022 [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock					400,000	400,000
December 2022 [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock		400,000
Warrants expiration date		Dec. 31, 2022
February 2021 [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock					460,000	460,000
February 2021 [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock		460,000
Warrants expiration date		Feb. 28, 2021
Subsequent To Issuance [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants exercised		425,000
Proceeds from the exercise of warrants		$ 4,250
Stock compensation expense		376,668
Business, Legal and Scientific Consultants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock					860,000	860,000
Warrants exercise price					$ 0.01	$ 0.01
Stock compensation expense		$ 336,926
Business, Legal and Scientific Consultants [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock		960,000
Warrants exercise price		$ 0.01
Private Placement [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock through private placements	$ 2,500		$ 224,000
Issuance of common stock	250,000		560,000
Stock price per share	$ 0.01		$ 0.40
Warrants exercise price	$ 0.01
Private Placement [Member] | Warrant One [Member]
Class of Stock [Line Items]
Issuance of common stock		250,000
Stock price per share		$ 0.40
Warrants issued to purchase common stock		250,000	310,000
Warrants exercise price		$ 0.75	$ 0.75
Warrants term period		3 years	3 years
Private Placement [Member] | Warrant Two [Member]
Class of Stock [Line Items]
Issuance of common stock		1,025,000
Stock price per share		$ 0.30
Warrants issued to purchase common stock		1,025,000	250,000
Warrants exercise price		$ 0.05	$ 0.01
Warrants term period		3 years	3 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	1 Months Ended					12 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares	Aug. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Aug. 31, 2016shares	Jan. 31, 2016USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)shares	Mar. 31, 2016shares	Jan. 31, 2016CAD ($)
Loss Contingencies [Line Items]
Additional issuance of common stock | shares							15,000
Research and development						$ 95,000	$ 171,078
Four New Member Scientific Advisory Board [Member]
Loss Contingencies [Line Items]
Warrants Issued to Purchase Common Stock | shares	35,000
Warrants exercise price | $ / shares	$ 0.01
Paid annual fee	$ 25,000
Stock compensation cost	$ 54,876
Research Agreement [Member]
Loss Contingencies [Line Items]
Research and development		$ 65,000	$ 130,000		$ 130,000
Agreement term			1 year		1 year
Agreement term, description			The Company paid these installment payments in July and October 2017 leaving no balance due
McGill [Member]
Loss Contingencies [Line Items]
Additional issuance of common stock | shares				300,000
Equity Method Investment, Ownership Percentage				5.00%
Series A financing [Member]
Loss Contingencies [Line Items]
Percentage of Issued and Outstanding Shares Issued As Milestone Payments								5.00%
Common Stock Shares Issued for Milestone Payment | shares								1,652,632
CAD Currency [Member]
Loss Contingencies [Line Items]
Annual royalty expense					$ 5,000
Royalty [Member]
Loss Contingencies [Line Items]
Annual revenue from royalty, percentage					3.00%
Androgen Replacement Treatment [Member] | CAD Currency [Member] | First US Patent [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									$ 5,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | Investigational New Drug Application or Regulatory Filing [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									25,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | First Phase II Clinical Study [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									50,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | First Phase III Clinical Study [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									100,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | Receipt of Regulatory Approval [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									300,000
Alzheimer Disease [Member] | CAD Currency [Member] | First US Patent [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									5,000
Alzheimer Disease [Member] | CAD Currency [Member] | Receipt of Regulatory Approval [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									200,000
Alzheimer Disease [Member] | CAD Currency [Member] | Filing of a 510(K) or PMA Application [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment									$ 50,000

Share-based Compensation (Detai

Share-based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	Mar. 31, 2017
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock			1,161,112
Warrants exercise price			$ 0.001
Share-based compensation	$ 463,299
Warrants expired common stock
Warrant expired date			Jan. 31, 2019
Scientific Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock				140,000
Warrants exercise price				$ 0.01
Share-based compensation	$ 54,876
Warrant expired date				Sep. 30, 2019
December 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock					400,000	400,000
Warrant expired date					Dec. 31, 2022	Dec. 31, 2022
December 2022 [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock	400,000
February 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock					460,000	460,000
Warrant expired date					Feb. 28, 2021	Feb. 28, 2021
February 2021 [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock	460,000
Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock							750,000
Warrants exercise price							$ 0.40
Share-based compensation	$ 20,502	$ 224,446
Business, Legal and Scientific Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock					860,000	860,000
Warrants exercise price					$ 0.01	$ 0.01
Share-based compensation	$ 336,926
Business, Legal and Scientific Consultants [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock	960,000
Warrants exercise price	$ 0.01
Business, Legal and Scientific Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock			100,000
Warrants exercise price			$ 0.01
Share-based compensation	$ 39,741
Warrant expired date			Oct. 31, 2023
CFO [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock			950,000
Corporate Secretary [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock			211,112

Share-based Compensation - Sche

Share-based Compensation - Schedule of Estimated Fair values of Warrants Granted Using the Black-Scholes Option Pricing Model (Details) - $ / shares	1 Months Ended				2 Months Ended
	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Feb. 28, 2018
Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate				1.55%
Expected term				3 years
Volatility rate				154.00%
Dividend yield				0.00%
Fair value				$ 0.33
Warrant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate, minimum			2.33%		2.33%
Risk free interest rate, maximum			2.34%		2.34%
Expected term			2 years 6 months		2 years 6 months
Volatility rate, minimum			115.00%		115.00%
Volatility rate, maximum			137.00%		137.00%
Dividend yield			0.00%		0.00%
Fair value			$ 0.39		$ 0.39
Warrant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate, minimum		2.49%
Risk free interest rate, maximum		2.57%
Expected term		1 year
Volatility rate		222.00%
Dividend yield		0.00%
Fair value		$ 0.39
Warrant Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.85%
Expected term	2 years 6 months
Volatility rate	237.00%
Dividend yield	0.00%
Fair value	$ 0.40
Warrant Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.41%
Expected term	2 years 6 months
Volatility rate	239.00%
Dividend yield	0.00%
Fair value	$ 0.40

Share-based Compensation - Sc_2

Share-based Compensation - Schedule of Warrant Activity (Details) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Warrants Outstanding and Exercisable, Beginning Balance	8,760,000	8,075,000
Warrants, Granted	4,061,112	935,000
Warrants, Expired/Cancelled
Warrants, Exercised	(425,000)	(250,000)
Warrants Outstanding and Exercisable, Ending Balance	12,396,112	8,760,000
Weighted-average Exercise Price, Outstanding and Exercisable, Beginning Balance	$ 0.35	$ 0.35
Weighted-average Exercise Price, Granted	0.13	0.41
Weighted-average Exercise Price, Expired/Cancelled
Weighted-average Exercise Price, Exercised	0.01	0.01
Weighted-average Exercise Price, Outstanding and Exercisable, Ending Balance	0.31	0.35
Weighted-average Grant Date Fair Value, Outstanding and Exercisable, Ending Balance	0.33	0
Weighted-average Grant Date Fair Value, Granted	0.39	0.33
Weighted-average Grant Date Fair Value, Expired/Cancelled
Weighted-average Grant Date Fair Value, Exercised
Weighted-average Grant Date Fair Value, Outstanding and Exercisable, Ending Balance	$ 0.36	$ 0.33

Share-based Compensation - Sc_3

Share-based Compensation - Schedule of Stock Options Exercise Price (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding | shares	12,396,112
Weighted-average exercise price	$ 0.37
Weighted-average remaining life	2 years 1 month 6 days
Exercise Price Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, minimum	$ 0.001
Exercise price range, maximum	$ 0.01
Number of options outstanding | shares	1,836,112
Weighted-average exercise price	$ 0.003
Weighted-average remaining life	1 year 10 months 25 days
Exercise Price Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, maximum	$ 0.05
Number of options outstanding | shares	1,025,000
Weighted-average exercise price	$ 0.05
Weighted-average remaining life	2 years 8 months 12 days
Exercise Price Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, maximum	$ 0.10
Number of options outstanding | shares	3,000,000
Weighted-average exercise price	$ 0.10
Weighted-average remaining life	1 year 7 months 6 days
Exercise Price Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, maximum	$ 0.40
Number of options outstanding | shares	750,000
Weighted-average exercise price	$ 0.40
Weighted-average remaining life	3 years 2 months 12 days
Exercise Price Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, maximum	$ 0.50
Number of options outstanding | shares	5,000,000
Weighted-average exercise price	$ 0.50
Weighted-average remaining life	1 year 7 months 6 days
Exercise Price Range Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, maximum	$ 0.75
Number of options outstanding | shares	785,000
Weighted-average exercise price	$ 0.75
Weighted-average remaining life	1 year 7 months 6 days

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Capitalized start-up costs	$ 3,041,165	$ 1,403,928
Amortized term	15 years
Valuation allowance	$ 638,645	$ 447,336

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Capitalized start-up costs	$ 638,645	$ 447,336
Deferred tax asset	638,645	447,336
Valuation allowance	(638,645)	(447,336)
Net deferred tax assets

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal income taxes at statutory rate	21.00%	34.00%
State income taxes at statutory rate	4.63%	4.63%
Valuation allowance	(25.63%)	(38.63%)
Effective tax rate	0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 05, 2019	Jan. 31, 2019	Jun. 30, 2018	Nov. 02, 2018
Research Agreement [Member] | Research Institute McGill University Health Centre [Member]
Subsequent Event [Line Items]
Payment for research and development			$ 65,000
Subsequent Event [Member] | Research Agreement [Member] | Research Institute McGill University Health Centre [Member]
Subsequent Event [Line Items]
Payment for research and development		$ 35,000
Mr. Duane C. Knight [Member]
Subsequent Event [Line Items]
Warrants Issued to Purchase Common Stock				950,000
Warrants exercise price				$ 0.001
Warrants term period				3 months
Mr. Thomas B. Olson [Member]
Subsequent Event [Line Items]
Warrants Issued to Purchase Common Stock				211,112
Warrants exercise price				$ 0.001
Warrants term period				3 months
Richard M. Schell [Member] | Subsequent Event [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Agreement extension period	2 years
Duane Knight [Member] | Subsequent Event [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Agreement extension period	2 years
Dr. Vassilios Papadopoulos [Member] | Subsequent Event [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Agreement extension period	1 year
Dr. Costas Karatzas [Member] | Subsequent Event [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Agreement extension period	2 years